|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Non Small Cell Lung Cancer | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Carcinoma, Non-Small-Cell Lung | |||||
| Lung Neoplasms | |||||
| 3 | More general conditions related to this trial | ||||
| Carcinoma | |||||
| Lung Diseases | |||||
| Neoplasms | |||||
| Neoplasms by Histologic Type | |||||
| Neoplasms by Site | |||||
| Neoplasms, Glandular and Epithelial | |||||
| Respiratory Tract Diseases | |||||
| Respiratory Tract Neoplasms | |||||
| Thoracic Neoplasms | |||||
| 4 | Interventions listed in this trial | ||||
| cetuximab + cisplatin + vinorelbine | |||||
| cisplatin + vinorelbine | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Cetuximab | |||||
| Cisplatin | |||||
| Vinorelbine | |||||
| 6 | More general drug interventions related to this trial | ||||
| Antineoplastic Agents | |||||
| Antineoplastic Agents, Phytogenic | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Radiation-Sensitizing Agents | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| Merck KGaA | |||||